IDEAYA Biosciences, Inc. (NASDAQ:IDYA) Shares Bought by Voloridge Investment Management LLC

Voloridge Investment Management LLC raised its holdings in IDEAYA Biosciences, Inc. (NASDAQ:IDYA) by 50.7% in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 286,759 shares of the company’s stock after acquiring an additional 96,466 shares during the quarter. Voloridge Investment Management LLC’s holdings in IDEAYA Biosciences were worth $7,370,000 as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors and hedge funds also recently bought and sold shares of the company. R Squared Ltd acquired a new stake in IDEAYA Biosciences in the 4th quarter valued at about $35,000. Daiwa Securities Group Inc. lifted its holdings in IDEAYA Biosciences by 44.0% in the 4th quarter. Daiwa Securities Group Inc. now owns 2,792 shares of the company’s stock valued at $72,000 after acquiring an additional 853 shares during the last quarter. KBC Group NV lifted its holdings in IDEAYA Biosciences by 84.6% in the 4th quarter. KBC Group NV now owns 4,197 shares of the company’s stock valued at $108,000 after acquiring an additional 1,923 shares during the last quarter. Cibc World Markets Corp acquired a new stake in IDEAYA Biosciences during the 4th quarter worth about $203,000. Finally, Mariner LLC raised its holdings in IDEAYA Biosciences by 9.8% during the 4th quarter. Mariner LLC now owns 9,775 shares of the company’s stock worth $251,000 after buying an additional 869 shares during the period. 98.29% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

IDYA has been the topic of several recent analyst reports. Stephens restated an “overweight” rating and set a $50.00 price objective on shares of IDEAYA Biosciences in a report on Friday, February 14th. JPMorgan Chase & Co. boosted their price objective on IDEAYA Biosciences from $63.00 to $66.00 and gave the stock an “overweight” rating in a report on Thursday. Two analysts have rated the stock with a hold rating, eleven have assigned a buy rating and one has issued a strong buy rating to the company’s stock. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus price target of $54.27.

IDEAYA Biosciences Price Performance

Shares of IDYA opened at $18.82 on Monday. The company has a market capitalization of $1.65 billion, a price-to-earnings ratio of -5.70 and a beta of 0.26. IDEAYA Biosciences, Inc. has a fifty-two week low of $13.45 and a fifty-two week high of $44.42. The business’s 50-day moving average is $17.65 and its 200-day moving average is $21.80.

IDEAYA Biosciences (NASDAQ:IDYA) last issued its earnings results on Tuesday, May 6th. The company reported ($0.82) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.75) by ($0.07). During the same quarter in the prior year, the business posted ($0.53) earnings per share. Equities research analysts expect that IDEAYA Biosciences, Inc. will post -3.07 earnings per share for the current fiscal year.

About IDEAYA Biosciences

IDEAYA Biosciences, Inc, a synthetic lethality-focused precision medicine oncology company, discovers and develops targeted therapeutics for patient populations selected using molecular diagnostics in the United States. The company's products in development include IDE196, a protein kinase C inhibitor that is in Phase 2/3 clinical trials for genetically defined cancers having GNAQ or GNA11 gene mutations; IDE397, a methionine adenosyltransferase 2a inhibitor that is in Phase 1/2 clinical trials for patients with solid tumors having methylthioadenosine phosphorylase gene deletions, such as non-small cell lung, bladder, gastric, and esophageal cancers; IDE161, a poly ADP-ribose glycohydrolase inhibitor that is in Phase 1 clinical trial to treat tumors with homologous recombination deficiency (HRD), and other genetic or molecular signatures; GSK101, a Pol Theta Helicase inhibitor that is in Phase 1 clinical trial for the treatment of tumors with BRCA or other homologous recombination, and HRD mutations; and Werner Helicase inhibitors for tumors with high microsatellite instability.